In line with these mechanistic findings, HSP90 inhibitors synergistically enhance antitumor effects of pemetrexed and MEK inhibitors in multiple in vitro and in vivo models, validating a rational combination strategy to treat KRAS-mutant lung cancer. Here, MAP2K7 is linked to lung carcinoma.